Edition:
United Kingdom

HBM Healthcare Investments AG (HBMN.S)

HBMN.S on Swiss Exchange

130.30CHF
4:03pm GMT
Change (% chg)

CHF-0.30 (-0.23%)
Prev Close
CHF130.60
Open
CHF130.60
Day's High
CHF131.20
Day's Low
CHF130.10
Volume
6,389
Avg. Vol
7,848
52-wk High
CHF132.00
52-wk Low
CHF98.15

Summary

Name Age Since Current Position

Hans Hasler

61 2010 Chairman of the Board of Directors

Andreas Wicki

58 2001 Chief Executive Officer

Heinz Riesenhuber

81 Vice Chairman of the Board of Directors

Erwin Troxler

47 2011 Chief Financial Officer

Benedikt Suter

53 Secretary to the Board of Directors

Mario Giuliani

45 2012 Member of the Board

Eduard Holdener

72 2008 Member of the Board

Robert Ingram

74 2006 Member of the Board

Rudolf Lanz

67 2003 Member of the Board

Biographies

Name Description

Hans Hasler

Mr. Hans Peter Hasler has been Chairman of the Board of Directors at HBM Healthcare Investments Ltd since June 25, 2010. He is Member of the Compensation Committee at the Company. He has been Member of the Board responsible for sector and marketing strategies at the Company since September 4, 2009. Between 1979 and 1980, he served as P&L Analyst at Swiss Bank Corporation. From 1980 till 1988 he worked at Sanofi Pharma AG. In years 1988-1992 he was Head of Pharma Division at Abbott AG. He served as General Manager at American Cynamid-Lederle from 1993 till 1994. In years 1995-1997 he was General Manager reporting to SVP Europe at Wyeth AG. He was Managing Director of Wyeth Group Germany from 1997 till 1998. From 1998 till 2001, he was Chief Marketing Officer / Head of Global Strategic Marketing, SVP and Member of the Wyeth Executive Steering Committee, Chairman of the Commercial Council Marketing responsibility to support sales of USD 10 billion at Wyeth Pharmaceuticals. He served as Head of Commercial Operations, worldwide responsibility (Strategic Marketing, Medical Affairs, Business Development, Shared Services, USA and International Organizations) at Biogen Inc. between 2001 and 2003. He acted as Senior Vice President, Head of International Organization at Biogen Idec International between 2004 and 2007. In years 2007-2009, he was Chief Operating Officer (COO), responsible for all Commercial Operations, Business Development, Medical Affairs and Biogen International and Head of Global Neurology/Cardiovascular Business at Biogen Idec Inc. Since 2014 he has been Member of the Board of Directors of AOP Orphan Pharmaceuticals AG and since 2016 of Dr. Reddy's Laboratories, among others. Mr. Hasler holds Swiss Federal Commercial Diploma, as well as Marketing Certificate from Swiss School of Business Administration SIB, Zurich.

Andreas Wicki

Dr. Andreas Wicki, Ph.D., has been Chief Executive Officer at HBM Healthcare Investments Ltd since 2001. He completed studies in chemistry and biochemistry at the Universitaet Bern, graduating in 1983, and earned the doctor's title at the Theodor Kocher Institute of the Universitaet Bern in 1986. He received an award for Research in the Area of Thrombosis and Haemostasis at the XI International Congress on Thrombosis and Haemostasis in Brussels, Belgium in 1987. From 1988 to 1990, he was Chief Executive Officer of Vivagen Diagnostics Ltd in Bern, Switzerland (sold to Unilabs Corp). He was also Investment advisor for life sciences with the private equity group APAX from 1993 till 1998. Subsequently, he served in ANAWA Holding AG / MDS Pharma Services Inc from 1991 to 2001. In 1991, he was named General Manager of the biomedicine division of ANAWA. In 1996, he became Chief Executive Officer of ANAWA. In 1998, he was appointed President of ANAWA Holding Ltd and Senior Vice President of European analytical operations for MDS Pharma Services. From 1998 to 2001, he was a venture capital advisor for life science investments with Private Equity Holding Ltd, a Vontobel Group company. Since 2001, he has been Chief Executive Officer of HBM BioVentures Ltd and HBM Partners Ltd. He founded Clinserve Ltd, where he was Chief Executive Officer from 1994 till 2000. Until end of April 2009 he was also Vice Chairman of the Board of Directors of Basilea Pharmaceutica Ltd. In addition, he has been Chairman of the Board of Directors of HBM Biopharma India Ltd. and Member of the Board of Directors of HBM BioVentures(Cayman) Ltd, Pacira Pharmaceuticals Ltd and HBM BioCapital Ltd, among others.

Heinz Riesenhuber

Prof. Dr. Heinz Riesenhuber serves as Vice Chairman of the Board of Directors at HBM Healthcare Investments Ltd. In the Company, he is responsible for management, including production and audit. In addition, he acts as Member of the Audit Committee at the Company. Prof. Dr. Riesenhuber has been with the Company since 2001. He completed studies in science and economics and became chartered chemist in 1961. Afterwards, he obtained his doctor's degree in chemistry in 1965 and was a postdoctoral fellow from 1962 to 1965. Since 1995 he has also been Honorary Professor at University of Frankfurt am Main, Germany. From 1966 to 1971, he served in Erzgesellschaft mgH in Frankfurt, Germany, where he was appointed Chief Executive Officer in 1968. Subsequently, from 1971 to 1982, he held the position of Chief Executive Officer in Synthomer Chemie GmbH in Frankfurt, Germany. From 1982 to 1993, Prof. Dr. Riesenhuber served as German Federal Minister of Research and Technology. Since 1976, he has been Member of the German Federal Parliament and has held the position of Member of the Committee on Economics and Technology since 1993. Since 1968 he has also acted as Member of the Presidential Board of Christian Democratic Party of Hessen. He also has been Member of the German Federal Parliament, since 1976, where, from 1993, he also is Member of the Committee on Economics and Technology, as well as Chairman of that Committee from 2001 till 2002. Since 2006 he is also Chairman of the German Parliamentary Society. Currently, Prof. Dr. Riesenhuber has been Member of the Investor Committee of Heidelberg Innovation BioScience Venture II GmbH since 2001, among others. He has Masters and Ph.D. degrees in chemistry from University of Frankfurt am Main, Germany as well as postdoctoral fellow.

Erwin Troxler

Mr. Erwin Troxler has been Chief Financial Officer of HBM Healthcare Investments Ltd since November 1, 2011. He joined HBM Healthcare Investments AG in 2005 and served within several areas of the Finance Department. Between 2002 and 2005, he was Deputy Branch Manager, responsible for investment companies in the private equity segment at Julius Baer Family Office, Zug, VP. Between 1999 and 2002, he was Audit Manager, responsible for audits of banks at PricewaterhouseCoopers Ltd, Lucerne. Between 1990 and 1993, he acted as Credit Administrator at Luzerner Kantonalbank, Reiden. Since 2014 he has been Chairman of the Swiss Association of Investment Companies (SAIC). He is Swiss Certified Public Accountant and holds a degree from Lucerne School of Economics and Business Administration (HWV) in 1996.

Benedikt Suter

Dr. Benedikt Suter is Secretary of the Board of Directors at HBM Healthcare Investments Ltd. From 1991 to 1992, he was a lawyer in the law firm Lenz Iselin Riggenbach in Basel. During 1993, he served in the commercial and cadastral registries of Canton Basel-Stadt. In 1994, he moved to law firms in London and Paris. Since 1995, he has been a lawyer and notary in Lenz Caemmerer Bender in Basel and Partner since 1999. He has also served as Member of the Board of Directors of Gebro Pharma Ltd, since 2004, Nef Group (Nef Automobile AG, Nef Management AG and NefTruckcenter AG) as Vice Chairman since 2002 as well as Member of the Board of Directors of SIC invent Ltd. since 2003. He holds Master’s degree, acquired in 1987, and doctorate, acquired in 1992, in law from the Universitaet Basel, Switzerland. He was admitted to the bar in 1990 and became notary of Canton Basel-Stadt in 1993.

Mario Giuliani

Mr. Mario Germano (Germano) Giuliani has been Member of the Board at HBM Healthcare Investments Ltd since 2012. He is Member of the Compensation Committee at the Company. He has a degree in Economics and Commerce from the Catholic, University of the Sacred Heart in Milan, Italy. He has served for Giuliani SpA, Italy since 1999 occupying several senior positions including President, Chief Executive Officer, Chief Financial Officer. He also served for Vector Fund Management, USA as Partner. He is Member of the Board of Directors and Member of the Investment Committee at Royalty Pharma and Member of the Investment Committee at Mosaix Ventures, LLP, among others.

Eduard Holdener

Dr. Eduard Enrico Holdener, M.D., has been Member of the Board of Directors at HBM Healthcare Investments Ltd since June 30, 2008. In the Company, he is responsible for research and development. From 1975 until 1976 Dr. Holdener was Resident in Neurology and Clinical Neurophysiology at Department of Neurology, Cantonal Hospital of St. Gallen. He was also, from 1976 till 1978, Fellow in Oncology at University of Kansas Medical Center in Kansas City, the United States. From 1978 till 1979 he served as Senior Consultant at Cantonal Hospital of Lucerne in Department of Medicine in Lucerne, Switzerland. From 1980 till 1986 he was Senior Consultant in Cantonal Hospital of St. Gallen, Department of Medicine, Division of Oncology & Hematology in St. Gallen. From 1986 till 1990, Dr. Holdener was Project Leader in Clinical Research in F. Hoffmann-La Roche Ltd in Basel. From 1991 till 1992 he was Global Head of Therapeutic Area Oncology/Immunology in Pharmaceutical Division at F. Hoffmann-La Roche Ltd. From 1993 till 1995 he was Deputy Head Global Clinical Research in Pharmaceutical Division at F. Hoffmann-La Roche. From 1996 till 1998 he was Head of Pharma Development Nippon Roche KK in Tokyo, Japan. From 1999 till 2006 he was Global Head of Pharma Development and Chief Medical Officer in Pharmaceutical Division at F. Hoffmann-La Roche and between 2006 and 2007, he acted as Chief Medical Officer (CMO) and Member of the Extended Corporate Executive Committee at F. Hoffmann-La Roche Ltd. Currently, Dr. Holdener has been Chairman of the Board of Directors of NovImmune SA, as well as Member of the Board of Directors of Parexel International Co. He graduated from Universitaet Zuerich, Medical Faculty and School of Medicine in Zuerich, Switzerland in November 1971. He holds a Doctorate in Medicine (MD) from Universitaet Basel, Medical Faculty in Basel, Switzerland in 1975.

Robert Ingram

Mr. Robert A. (Bob) Ingram has been Member of the Board at HBM Healthcare Investments Ltd since 2006. He is responsible for sector and marketing strategies. He is also Member of the Compensation and the Nominating Committee at the Company. From 1965 till 1985 he was Vice President Public Affairs at Merrell Dow Pharmaceuticals Inc in Cincinnati, Ohio. From 1985 till 1990 he served at Merck & Co Inc in Rahway, New Jersey first as President of Merck Frosst Canada, in 1988, and then as Vice President of Government Affairs, in 1985. Between 1990 and 2010 he served at GlaxoSmithKline Plc. In 1990 he became Executive Vice President of Administrative and Regulatory Affairs, followed by Group Vice President of Glaxo Inc, a subsidiary of Glaxo Plc. In June, 1993 he became President and Chief Operating Officer and, in January, Executive Vice President. He then became, in 1994, President and Chief Executive Officer. In 1995 Mr. Ingram was appointed to the global Board as Executive Director of Glaxo Wellcome Plc. In 1997 he became Chief Executive Officer of Glaxo Wellcome Plc. In 1999 he became Chairman of the Board of Directors. Beginning with 2001, he subsequently served as President and COO pharmaceutical operations, Vice Chairman Pharmaceuticals and in 2010 as Advisor to the CEO. Furthermore, since 2007, Mr. Ingram has been General Partner at Hatteras Ventures Partners. Currently, he acts as Member of the Board of Directors at BioCryst Pharmaceuticals Inc, among others. He graduated from Eastern Illinois University, Lumpkin college of Business, with a Bachelor of Science degree in business administration.

Rudolf Lanz

Dr. Rudolf Lanz has been Member of the Board of Directors at HBM Healthcare Investments Ltd since 2003. He is Member of the Audit Committee and Nominating Committee at the Company. From 1976 to 1977, he served in ATAG Allgemeinen Treuhand Ltd. Basel Assurance and Advisory Department. From 1980 to 2000, he worked as Partner in Ernst & Young Ltd in Zurich and Bern, from 1997 to 2000 as Member of the Executive Committee and subsequently, from 1995 to1999, as Chief Financial Officer. From 1994 to 1997, he was a Member of the Board of Directors. From 1988 to 2000, he was Head of Mergers & Acquisitions / Corporate Finance. Between 2000 and 2009 he has served as Chairman of the Board of Directors of The Corporate Finance Group (TCFG), an independent mergers and acqusitions /corporate finance consulting firm, focusing on transactions services for companies. Currently, he acts as Member of the Board of Directors of MIAC AG and Pearls Fashion Holding AG. He also serves as Chairman of the Board of Directors at Dr. Rudolf Lanz AG. He holds a Master's degree in economics from Universitaet St. Gallen and doctorate in law from Universitaet Bern.

Basic Compensation

Name Fiscal Year Total

Hans Hasler

355,500

Andreas Wicki

185,404

Heinz Riesenhuber

348,928

Erwin Troxler

95,000

Benedikt Suter

--

Mario Giuliani

301,371

Eduard Holdener

286,494

Robert Ingram

282,500

Rudolf Lanz

305,500
As Of  31 Mar 2017